Evaluating the safety and efficacy of zuranolone in the management of major depressive disorder and postpartum depression, with or without concurrent insomnia: a rigorous systematic review and meta-analysis DOI Creative Commons
Adarsh Raja,

Saboor Ahmed,

Muhammad Basit Ali Siddiqui

и другие.

Frontiers in Psychiatry, Год журнала: 2024, Номер 15

Опубликована: Июль 5, 2024

Introduction Major depressive disorder (MDD), postpartum depression (PPD), and insomnia are neuropsychological conditions in which zuranolone is used to improve symptoms prognosis of the disorder. This meta-analysis aimed determine efficacy comparison other drugs for treating these conditions. Methods included patients aged between 18 75 years who were diagnosed with major or without administered treatment. Only randomized controlled trials (RCTs) included, animal studies excluded. The databases PubMed, Scopus, Cochrane, Clinicaltrials.gov, MeSH terms relevant keywords (Zuranolone) (Depression). Cochrane risk bias tool was quality assessment. Results eight RCTs that analyzed data from 2031 patients. revealed statistically significant changes Hamilton Depression Rating Scale (HAM-D), Montgomery-Åsberg (MADRS), Anxiety (HAM-A), treatment-emergent adverse effects (TEAE) scores PPD subgroup. HAM-D TEAEs also MDD subgroup, but MADRS, HAM-A, Bech-6 insignificant. Serious events insignificant all subgroups. Conclusion Meta-analysis found a improvement treatment, especially on day 15. suggests promising therapeutic option insomnia. Systematic review registration https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=459554 , identifier CRD42023459554.

Язык: Английский

Mental Health Disorders in Pregnancy and the Early Postpartum DOI Creative Commons

Zena Schofield,

Zack Schofield

Опубликована: Янв. 18, 2025

Mental health disorders are common in pregnancy and after childbirth with over 10% of women manifesting some form mental illness during this time. Maternity services will encounter symptoms that vary severity from mild self-limiting to potentially life-threatening. These conditions carry risks for both the woman fetus/newborn. Detecting with, or at risk of, a serious disorder enabling them access appropriate care timely fashion is shared responsibility. However, given frequency contact they have through period, maternity pivotal role. From perspective, high-risk pregnancies those primarily associated (psychotic illnesses, bipolar severe depressive episodes). Healthcare professionals caring pregnant should skills detect identify how specialist care.

Язык: Английский

Процитировано

1
Clinical Utility of Zuranolone for Postpartum Depression: A Narrative Review DOI Creative Commons

Athanasia Giannopoulos,

Joshna Singh,

Kristina M. Deligiannidis

и другие.

Neuropsychiatric Disease and Treatment, Год журнала: 2025, Номер Volume 21, С. 93 - 105

Опубликована: Янв. 1, 2025

Peripartum depression (PPD) affects approximately one in every eight birthing individuals. Despite a high prevalence, PPD is underdiagnosed and undertreated. Several treatment options exist including psychotherapies, conventional serotonergic-based antidepressants alternative integrative medicine approaches. Rapid-acting neuroactive steroid-based have been studied approved the United States (US) for of adult females with PPD. Zuranolone first US Food Drug Administration oral antidepressant This narrative review reports on evidence clinical utility zuranolone treatment. In double-blind, randomized, placebo-controlled, trials, demonstrated rapid, statistically significant clinically meaningful improvements depressive symptoms. Most common adverse events reported use were somnolence, dizziness, sedation, headache. No changes vital signs, electrocardiogram or lab parameters observed. loss consciousness no increase suicidal ideation from baseline deaths seen studies. Secondary analyses that improves comorbid symptoms anxiety insomnia some measures health-related quality life. relevant infant dose lactation data suggest its compatible breastfeeding, though future research needed to measure potential effects breastfed infant. Key aspects decision-making patients are discussed.

Язык: Английский

Процитировано

1
The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis DOI

Mackenzie Winslow,

Emily White, Suzanne J. Rose

и другие.

International Journal of Clinical Pharmacy, Год журнала: 2024, Номер 46(3), С. 590 - 601

Опубликована: Март 15, 2024

Язык: Английский

Процитировано

6
Effect of intraoperative and/or postoperative esketamine administration on preventing postpartum depression: A systematic review and meta-analysis DOI
Jinping Wang, Hui Liu,

Xinchuan Wei

и другие.

Psychiatry Research, Год журнала: 2024, Номер 335, С. 115890 - 115890

Опубликована: Апрель 2, 2024

Язык: Английский

Процитировано

6
Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions DOI
Cindy‐Lee Dennis, Daisy R. Singla, Hilary K. Brown

и другие.

Drugs, Год журнала: 2024, Номер 84(6), С. 645 - 659

Опубликована: Май 30, 2024

Язык: Английский

Процитировано

6
Current pharmacotherapy approaches and novel GABAergic antidepressant development in postpartum depression DOI Creative Commons
Sara V. Carlini, Lauren M. Osborne, Kristina M. Deligiannidis

и другие.

Dialogues in Clinical Neuroscience, Год журнала: 2023, Номер 25(1), С. 92 - 100

Опубликована: Окт. 5, 2023

Postpartum depression has deleterious effects on childbearing persons globally. Existing treatments have been largely extrapolated from those for other forms of and included pharmacotherapy, psychotherapy, neuromodulation. Hormonal with oestrogen progestogens, thought to be a rational approach treatment in response an emerging literature the pathophysiology postpartum depression, only limited evidence efficacy date. Novel antidepressant development allopregnanolone analogues, contrast, proven promising avenue rationally designed efficacious treatments. This state-of-the-art review presents current standard-of-care hormonal treatment, analogues along discussion understanding its neuroactive steroid-driven pathophysiology.

Язык: Английский

Процитировано

12
Efficacy and tolerability of zuranolone in patients with depression: a meta-analysis of randomized controlled trials DOI Creative Commons

Youjia Qiu,

Yuchen Tao,

Aojie Duan

и другие.

Frontiers in Pharmacology, Год журнала: 2024, Номер 14

Опубликована: Янв. 15, 2024

Background: As a novel antidepressant drug, zuranolone has been initially applied in treating depression. This study investigated the efficacy and safety of its administration patients with Methods: The Embase, PubMed, Cochrane library databases were searched for available studies up to 1 Nov 2023. primary outcome was change on day 15 depression severity scores compared baseline. Secondary outcomes included remission response rates 15. Safety incidence treatment-emergent adverse events (TEAEs) individual AEs. Trial sequential analysis (TSA) used evaluate ideal samplesize. Results: Six 1884 included. Zuranolone offered significantly greater changes (mean difference = 2.43, 95% confidence interval [CI]: 1.36 3.49, p < 0.00001) placebo; this also observed at other time points. Differences (relative risk [RR] 1.33, CI: 1.15 1.54, 0.0001) (RR 1.46, 1.85, 0.002) statistically significant. For outcomes, group showed more TEAE than placebo (RR: 1.15, 1.06 1.25, 0.0005, I 2 0%). AEs, significant differences dizziness 2.17, 1.22 3.86, 0.008) somnolence 1.35 4.37, 0.003. No result TSA indicated that cumulative curve crossed conventional (Z 1.96) boundary but not reach (RIS 1910). Conclusion: Our findings suggest rapid short-term effect during administration. Although TEAEs zuranolone, most them slight temporary. However, larger sample sizes longer follow-up are needed. Systematic Review Registration: https://inplasy.com/inplasy-2023-5-0104/ , identifier INPLASY202350104.

Язык: Английский

Процитировано

5
Zuranolone: A Narrative Review of a New Oral Treatment for Postpartum Depression DOI

Emily M. Hitt

Clinical Therapeutics, Год журнала: 2024, Номер 46(5), С. 433 - 438

Опубликована: Май 1, 2024

Язык: Английский

Процитировано

5
Zuranolone Concentrations in the Breast Milk of Healthy, Lactating Individuals DOI Creative Commons
Kristina M. Deligiannidis, Amy Bullock,

Indrani Nandy

и другие.

Journal of Clinical Psychopharmacology, Год журнала: 2024, Номер unknown

Опубликована: Май 13, 2024

Abstract Purpose/Background Zuranolone is a positive allosteric modulator of both synaptic and extrasynaptic γ-aminobutyric acid type A receptors neuroactive steroid approved as an oral, once-daily, 14-day treatment course for adults with postpartum depression in the United States. This study assessed zuranolone transfer into breast milk. Methods/Procedures Healthy, nonpregnant, lactating adult female participants received once-daily 30 mg from day (D)1 through D5 this phase 1 open-label study. The relative infant dose (RID; weight-adjusted proportion maternal milk over 24 hours) was at D5. An RID 50 estimated using simulation approach across range ages weights. Findings/Results Of 15 enrolled (mean age, 30.1 years), 14 completed mean 0.357%; steady-state volume D3 to decreased baseline by 8.3%. Overall unbound plasma low (≤0.49%). Plasma concentrations peaked before decreasing biexponential manner. There strong concordance between temporal evolution based on intake 200 mL/kg per 0.984%. All treatment-emergent adverse events reported were mild, most common being dizziness (n = 3). Implications/Conclusions healthy, low; <1%, well below <10% threshold generally considered compatible breastfeeding.

Язык: Английский

Процитировано

5
The emergence of antidepressant drugs targeting GABAA receptors: A concise review DOI Creative Commons
Xénia Gonda, Frank I. Tarazi, Péter Döme

и другие.

Biochemical Pharmacology, Год журнала: 2024, Номер 228, С. 116481 - 116481

Опубликована: Авг. 13, 2024

Depression is among the most common psychiatric illnesses, which imposes a major socioeconomic burden on patients, caregivers, and public health system. Treatment with classical antidepressants (e.g. tricyclic selective serotonine reuptake inhibitors), primarily affect monoaminergic systems has several limitations, such as delayed onset of action moderate efficacy in relatively large proportion depressed patients. Furthermore, depression highly heterogeneus, its different subtypes, including post-partum depression, involve distinct neurobiology, warranting differential approach to pharmacotherapy. Given these shortcomings, need for novel that are superior faster fully justified. The development market introduction rapid-acting accelerated recent years. Some new act through GABAergic In this review, we discuss discovery, efficacy, limitations treatment classic antidepressants. We provide detailed discussion neurotransmission, special focus GABA

Язык: Английский

Процитировано

5